Modulating TREM2 with Multiple Modalities to Treat Rare Genetically Defined Microgliopathies (VGL101) & Alzheimer’s Disease (VG-3927)

Time: 3:00 pm
day: Conference Day One

Details:

  • Navigating VG-3927 small molecule approach to TREM2 agonism to address unmet needs in Alzheimer’s Disease
  • Exploring phase 2 results of targeting rare genetically defined microgliopathies with Iluzanebart (VGL101) for ALSP2 by increasing signaling through DAP12/SYK to mitigate microglial dysfunction downstream
  • Navigating genetic and biomarker strategies to aid early development and how a small molecule TREM2 agonist may address the unmet needs in Alzheimer’s and beyond

Speakers: